RecruitingHepatocellular Carcinoma

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.

Sponsor: Inova Health Care Services

You may qualify if…

✓ 1. Age 18 or older.
✓ 2. Patients have newly diagnosed and previously untreated, histologically or radiologically confirmed hepatocellular carcinoma with at least one lesion that is measurable by RECIST 1.1 criteria. A prior HCC lesion that was treated surgically or by radiation is allowed as long as it was at least 2 years or more from the current HCC diagnosis.
✓ 3. Patient's cancer must be deemed locally advanced and unresectable
✓ 4. Patients must have a Childs-Pugh cirrhosis score of A5 or A6.
✓ 5. Eastern Cooperative Oncology Group Performance Status of 0-1.
✓ 6. Patients must have bone marrow and organ function as defined below:
✓ Absolute Neutrophil Count ≥ 1,500/μL
✓ Platelets ≥ 100,000/μL

You may not qualify if…

✕ 1. Patients with Childs-Pugh B or C cirrhosis.
✕ 2. Female patients who are pregnant or breast-feeding.
✕ 3. Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.
✕ 4. Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study. This would include any uncontrolled or untreated viral infection such as HIV, HBV, HCV etc.
✕ 5. Subject is enrolled in a separate interventional clinical trial.
✕ 6. Active tuberculosis.
✕ 7. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
✕ 8. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.

Where it's recruiting

Virginia

Fairfax · Falls Church

Source: ClinicalTrials.gov · NCT06789757 · last updated 2025-10-07